Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 study with IN-001 in healthy volunteers

Next Previous
X
Search
Trial Profile

A Phase 1 study with IN-001 in healthy volunteers

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dipivefrine (Primary) ; Epinephrine
  • Indications Anaphylaxis
  • Focus Adverse reactions

    • Most Recent Events

    • 05 Nov 2020 New trial record
    • 29 Oct 2020 According to an Insignis Therapeutics media release, if this study is successful, under the 505(b)(2) regulatory pathway, Insignis and HLK Pharmacin would begin preparations to initiate a pivotal study in the second half of 2021.
    • 29 Oct 2020 According to an Insignis Therapeutics media release, the company and HLK Pharmacin announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IN-001, an oral formulation of an epinephrine prodrug for life-saving treatment of allergic reactions, including anaphylaxis. Under this IND, the companies are prepared to initiate a Phase 1 study this quarter and intends to have clinical data in first half of 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top